BioStem Technologies (BSEM) director receives 7,671 shares
Rhea-AI Filing Summary
BioStem Technologies, Inc. (BSEM) director Steven D. Sonenreich reported the vesting and conversion of 7,671 Restricted Stock Units into 7,671 shares of common stock on August 27, 2026. Each RSU represented a contingent right to receive one common share. Following the transaction, he directly held 7,671 shares of common stock and no remaining RSUs from this grant.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 7,671 shares
Net Buy
2 txns
Insider
SONENREICH STEVEN D
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units F1, F2 | 7,671 | $0.00 | $0.00 |
| Exercise | Common Stock | 7,671 | $0.00 | $0.00 |
Holdings After Transaction:
Restricted Stock Units — 0 shares (Direct);
Common Stock — 7,671 shares (Direct)
Footnotes (2)
- F1. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
- F2. These restricted stock units vested on August 27, 2026.
Key Figures
Restricted Stock Units exercised: 7,671 units
Common Stock acquired from RSU conversion: 7,671 shares
Common Stock holdings after transaction: 7,671 shares
+3 more
6 metrics
Restricted Stock Units exercised
7,671 units
RSUs converted into common stock on August 27, 2026
Common Stock acquired from RSU conversion
7,671 shares
Shares received upon RSU exercise on August 27, 2026
Common Stock holdings after transaction
7,671 shares
Direct ownership reported following the August 27, 2026 transaction
RSUs remaining after conversion
0 units
RSU position from this grant after August 27, 2026 vesting
Exercise price per share
$0.00 per share
Reported for the RSU-to-common-stock conversion on August 27, 2026
Exercise or conversion of derivative security
1 transaction
Code M event converting RSUs into common stock
Key Terms
Restricted Stock Units, contingent right, vested, Exercise or conversion of derivative security
4 terms
Restricted Stock Units financial
"Each restricted stock unit represents a contingent right to receive one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
contingent right financial
"represents a contingent right to receive one share of the issuer's"
vested financial
"These restricted stock units vested on August 27, 2026."
Exercise or conversion of derivative security financial
"transaction_code_description":"Exercise or conversion of derivative security"
FAQ
What insider transaction did BioStem Technologies (BSEM) disclose in this Form 4?
The filing reports that director Steven D. Sonenreich exercised and converted 7,671 Restricted Stock Units into 7,671 shares of BioStem Technologies common stock on August 27, 2026, at a reported exercise price of $0.00 per share.
What happened to the Restricted Stock Units reported for BSEM on August 27, 2026?
On August 27, 2026, 7,671 Restricted Stock Units vested and were converted into 7,671 shares of common stock. The RSU position went to 0 following this exercise and conversion event.
What does each Restricted Stock Unit represent in the BSEM Form 4 filing?
Each Restricted Stock Unit represents a contingent right to receive one share of BioStem Technologies common stock. Upon vesting, the RSUs are settled in common shares on a one-for-one basis, as disclosed in the footnotes.
Was the BioStem Technologies (BSEM) Form 4 transaction under a Rule 10b5-1 plan?
No. The filing’s Rule 10b5-1 checkbox is not affirmed (aff_10b5_one is false), and the footnotes do not state that the transaction was executed pursuant to a Rule 10b5-1 trading plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
